Differentiation of organ availability by sequential and simultaneous analyses: Intestinal conjugative metabolism impacts on intestinal availability in humans

Journal of Pharmaceutical Sciences

Volumn 94, Issue 3, 2005, Pages 571-575

  Mizuma, Takashi ^a   Kawashima, Kosuke ^b   Sakai, Shuichi ^b   Sakaguchi, Sayaka ^a   Hayashi, Masahiro ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bioavailability; Conjugation; Intestinal metabolism; Pharmacokinetics; Phase II enzymes

Indexed keywords

ETHINYLESTRADIOL; SALBUTAMOL; TERBUTALINE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG METABOLISM; DRUG SULFATION; HUMAN; INTESTINE; LIVER CLEARANCE; SEQUENTIAL ANALYSIS;

EID: 16444374977     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20269     Document Type: Article

References (17)

1. Rowland M, Tozer TN. 1995. Clinical pharmacokinetics. Concept and applications. Philadelphia: Williams & Willkins, pp 119-136.
2. Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomes DY, Wacher VJ. 1995. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 58:492-497.
3. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
4. Koster AS, Hofman GA, Frankhuijzen-Sierevogel AC, Noordhoek J. 1985. Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. Drug Metab Dispos 13:464-470.
5. Mistry M, Houston B. 1987. Glucuronidation in vitro and in vivo: Comparison of intestinal and hepatic conjugation of morphine, naloxone and buprenorphine. Drug Metab Dispos 15:710-717.
6. Brewster D, Humphrey MJ, McLeavy MA. 1981. The systemic bioavailability of buprenorphine by various routes of administration. J Pharm Pharmacol 33:500-506.
7. Mizuma T, Awazu S. 1998. Inhibitory effect of phloridzin and phloretin on glucuronidation of p-nitrophenol, acetaminophen and 1-naphthol: Kinetic demonstration of the influence of glucuronidation metabolism on intestinal absorption in rats. Biochim Biophys Acta 1425:398-404.
8. Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP. 1986. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 22:587-593.
9. Ripe E, Hornblad Y, Tegner K. 1984. Oral administration of terbutaline in asthmatic patients. Eur J Respir Dis Suppl 134:171-179.
10. Back DJ, Bolt HM, Breckenridge AM, Crawford FE, Orme ML, Rowe PH, Schindler AE. 1980. The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women. Contraception 21:145-153.
11. Mizuma T. 2002. Kinetic impact of presystemic intestinal metabolism on drug absorption: Experiment and data analysis for the prediction of in vivo absorption from in vitro data. Drug Metab Pharmacokinet 17:496-506.
12. Hulten L, Lindhagen J, Lundgren O. 1977. Sympathetic nervous control of intramural blood flow in the feline and human intestines. Gastroenterology 72:41-48.
13. Borgstrom L, Nyberg L, Jonsson S, Clindberg C, Paulson J. 1989. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br J Clin Pharmacol 27:49-56.
14. Lennernas H. 1997. A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: In vivo permeability estimation. J Pharm Pharmacol 49:682-686.
15. Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orme ML, Rowe PH, Watts MJ. 1979. An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception 20:263-273.
16. Vietri M, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. 2000. Differential inhibition of hepatic and duodenal sulfation of (-)-salbutamol and minoxidil by mefenamic acid. Eur J Clin Pharmacol 56:477-479.
17. Pacifici GM, Eligi M, Giulianin L. 1993. (+) and (-) terbutaline are sulphated at a higher rate in human intestine than in liver. Eur J Clin Pharmacol 45:483-487.